Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Cara Therapeutics Inc. (NASDAQ: CARA) Leading the Way in Friday Trading Based on Percentage Gain By: Investor Brand Network September 15, 2023 at 11:25 AM EDT Cara Therapeutics, Inc. (NASDAQ: CARA) is one of today’s top gainers. The company’s shares are currently up 16.42% on the day to $2.41. Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus. So far today, approximately 1.06M shares of Cara Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 507.48k shares. Cara Therapeutics, Inc. share prices have moved between a 52-week high of $12.81 and a 52-week low of $1.7. The stock has moved -1.8% over the past week. To learn more about Cara Therapeutics, Inc., visit the company’s website at https://www.caratherapeutics.com. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Cara Therapeutics Inc. (NASDAQ: CARA) Leading the Way in Friday Trading Based on Percentage Gain By: Investor Brand Network September 15, 2023 at 11:25 AM EDT Cara Therapeutics, Inc. (NASDAQ: CARA) is one of today’s top gainers. The company’s shares are currently up 16.42% on the day to $2.41. Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus. So far today, approximately 1.06M shares of Cara Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 507.48k shares. Cara Therapeutics, Inc. share prices have moved between a 52-week high of $12.81 and a 52-week low of $1.7. The stock has moved -1.8% over the past week. To learn more about Cara Therapeutics, Inc., visit the company’s website at https://www.caratherapeutics.com. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com
Cara Therapeutics, Inc. (NASDAQ: CARA) is one of today’s top gainers. The company’s shares are currently up 16.42% on the day to $2.41. Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus. So far today, approximately 1.06M shares of Cara Therapeutics, Inc. have been exchanged, as compared to an average 30-day volume of 507.48k shares. Cara Therapeutics, Inc. share prices have moved between a 52-week high of $12.81 and a 52-week low of $1.7. The stock has moved -1.8% over the past week. To learn more about Cara Therapeutics, Inc., visit the company’s website at https://www.caratherapeutics.com. Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected About IBN IBN consists of financial brands introduced to the investment public over the course of 17+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients. Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions. For more information, please visit https://www.InvestorBrandNetwork.com Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer IBNLos Angeles, Californiawww.InvestorBrandNetwork.com310.299.1717 OfficeEditor@InvestorBrandNetwork.com